CDNA Earnings Date: Mar 3, 2027 (Estimated) — CareDx, Inc
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is CDNA's next earnings date?
CareDx, Inc (CDNA) is expected to report Q4 2026 earnings on Wednesday, March 3, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.21 on revenue of $123.5M.
How did CDNA do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), CareDx, Inc posted EPS of $0.70 versus the $0.25 estimate, a beat of 174.7%. Revenue was $139.4M against a $122.0M estimate.
How much does CDNA stock move after earnings?
CDNA beat EPS estimates in 7 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 8.1% (up or down) in the day after earnings.
About CareDx, Inc
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
🤖 AI Earnings Analysis
CareDx posted a strong diagnostics quarter, with revenue up 39% to $139M and EPS of $0.70 beating estimates by $0.45. Yet an $11M operating loss tempers confidence in earnings quality.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 0.25 | 0.70 | +174.73% | $139.4M | ✅ Beat | — | — | — |
| 2026-07-30 | Q2 2026 | 0.20 | 0.37 | +85.00% | $131.9M | ✅ Beat | +14.72% | +17.61% | +30.68% |
| 2026-04-28 | Q1 2026 | 0.08 | 0.34 | +325.00% | $117.7M | ✅ Beat | -5.07% | -5.52% | +3.61% |
| 2026-02-24 | Q4 2025 | 0.23 | 0.12 | -47.83% | $108.4M | ❌ Miss | -4.10% | -2.34% | -6.08% |
| 2025-11-04 | Q3 2025 | 0.04 | 0.28 | +600.00% | $100.1M | ✅ Beat | +13.84% | +15.56% | +33.68% |
| 2025-08-06 | Q2 2025 | 0.03 | 0.10 | +233.33% | $86.7M | ✅ Beat | -7.86% | -7.40% | +5.50% |
| 2025-04-30 | Q1 2025 | 0.07 | 0.09 | +28.57% | $84.7M | ✅ Beat | -10.72% | -12.50% | +0.65% |
| 2025-02-26 | Q4 2024 | 0.15 | 0.18 | +20.00% | $86.6M | ✅ Beat | -0.19% | -3.22% | -13.03% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q3 FY26 · $139.4M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.6% | $138.8M | +46.0% | $79.9M | $81.6M | $95.1M | $103.4M |
| Non-US | 0.4% | $554K | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.